On March 26, 2026, Chengdu Olymvax Biopharmaceuticals Inc. (hereinafter referred to as “Olymvax”, Stock Code: 688319) and Westlake University officially signed a cooperation agreement. Following multiple on-site inspections and in-depth preliminary communications with the Center for Emergency Medicine Research of Westlake University, the two parties will integrate their core strengths in basic scientific research and industrial transformation, forge an in-depth strategic cooperative partnership, and jointly advance the early research and development of broad-spectrum (universal) influenza vaccines.
Seasonal influenza epidemics bring severe health challenges and economic burdens to the public. Vaccination is the most cost-effective and efficient measure for influenza prevention. Hence, the development of broad-spectrum influenza vaccines capable of providing broader and longer-lasting protection has become a cutting-edge trend in the global vaccine industry.
The Center for Emergency Medicine Research of Westlake University has laid a solid scientific research foundation in this field, while Olymvax boasts mature and proven experience in vaccine industrialization. This cooperation serves as a key initiative for Olymvax to further implement its dual-wheel drive strategy of “independent R&D + joint R&D”. It marks the Company’s influenza vaccine R&D layout shifting toward broad-spectrum and pioneering directions, and will help elevate the overall technological research and development as well as industrialization level of China’s universal influenza vaccine sector.
Taking this cooperation as an opportunity, the two sides will establish a joint R&D and information sharing mechanism, fully unleash the synergy of industry-university-research collaborative innovation, jointly develop new-generation influenza vaccines with broad protection coverage, break through existing technical bottlenecks, and provide more effective prevention options for the public.
Dr. Fan Fan, Vice Chairman of Olymvax, noted that the cooperation with Westlake University is a vital step for the Company to integrate high-end scientific research resources and accelerate the R&D of innovative vaccines. The complementary advantages of both parties will greatly boost research and development efficiency and facilitate the rapid industrialization of cutting-edge scientific and technological achievements. Moving forward, Olymvax will continue to deepen collaboration with universities and research institutions, focus on urgent public health needs, and underpin the high-quality innovative development of the vaccine industry.
Dr. Fan Fan further emphasized that broad-spectrum influenza vaccines represent the key upgrading direction of influenza vaccines and a core future development strategy. While steadily promoting the R&D of cell-based influenza vaccines and improving product pipelines covering trivalent influenza vaccines, quadrivalent influenza vaccines and adjuvanted influenza vaccines, Olymvax has always maintained a long-term focus on the influenza vaccine track. This collaboration with Westlake University fully reflects the Company’s commitment to developing foundational solutions for disease prevention with a forward-looking vision. As the cooperation progresses in depth, the two parties are expected to secure breakthroughs in core key technologies and contribute a valuable Chinese solution to safeguarding global public health.